Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
almonertinib + SHR-1701
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Almonertinib is a third-generation small molecule EGFR tyrosine kinase inhibitor that targets both EGFR-sensitizing and T790M resistance mutations, primarily developed for the treatment of advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC)[8]. SHR-1701, also known as retlirafusp alfa, is a bifunctional recombinant fusion protein composed of an anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II. This design enables dual inhibition of PD-L1 and TGF-beta signaling pathways, aiming to enhance antitumor immune responses[5][2][3]. The combination of almonertinib with SHR-1701 is being investigated in clinical trials for relapsed or advanced malignancies, including NSCLC and other solid tumors[1][4].
- Brand names
- Ameile
- Other names
- aumolertinib (for almonertinib)retlirafusp alfa (for SHR-1701)
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)EGFR (Epidermal growth factor receptor)TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on almonertinib + SHR-1701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on almonertinib + SHR-1701.